Objective To evaluate the mid-term outcomes of sirolimus-eluting stents (SES; Cypher Bx Velocity) for de novo coronary stenosis in a Japanese clinical setting, and to compare these with the outcomes using baremetal stents (BMS). Methods This study was a nonrandomized, lesion-based, and single-center study, retrospectively investigated in October 2010. We enrolled 2031 consecutive cases with de novo coronary lesions treated with BMS (n=587) or SES (n=1,444) from January 2003 to May 2007. SES use ratio during the available interval was 95.5%. The primary endpoint was the incidence of target vessel failure (TVF: comprising cardiac death, nonfatal recurrent MI, definite stent thrombosis (ST), and severe restenosis [% diameter stenosis (%DS) at secondary angiography !70%]. The secondary endpoint was the incidence of binary in-stent restenosis (%DS > 50%). Results The TVF ratio after SES placement (6.6%) was significantly lower than that after BMS placement (11.8%, p<0.001), despite many disadvantageous variables in the SES group. SES related to the risk of TVF (mean follow-up for SES, 1,411 ± 539 days; BMS, 1,818 ± 825 days) (hazard ratio of 0.428 at 95% CI, 0.292-0.627, p<0.001). The ratio of binary in-stent restenosis after SES placement (13.4%) was significantly lower than that after BMS placement (25.1%; p<0.001). SES was significantly related to binary in-stent restenosis (odds ratio of 0.267 at 95% CI, p<0.001). Conclusion SES has a more favorable mid-term clinical and angiographic outcome than BMS for de novo coronary stenosis in clinical settings in Japan.
Introduction
Sirolimus-eluting stents (SES: Cypher ; Cordis, Johnson & Johnson, Miami, Florida) were widely used in daily practice in Japan, not only because of their efficacy compared to that of bare metal stents (BMS), but also because of their short-term safety with a lower incidence of devastating stent thrombosis (ST) in Japan compared with that in Western countries (1) (2) (3) (4) (5) . However, the long-term safety and efficacy of SES for widespread use in Japan is not fully understood.
In the present study, we retrospectively examined the mid-term clinical and angiographic outcomes of SES used as a single drug-eluting stent (DES) in a clinical setting from August 2004 to May 2007. The incidences and the predictors of cardiac events and binary in-stent restenosis of SES were examined through a historical comparison with those of BMS used in 2,031 consecutive nonrandomized de novo native coronary lesions treated by either SES or BMS in 1,584 patients.
Methods

Population
The present study was a lesion-based, retrospective, nonrandomized, single-center study, as largely determined by a historical comparison with the outcomes of BMS in our previous reports (6, 7) . The rationale of almost unrestricted use of SES has been previously reported (2, (5) (6) (7) . From January 2003 to August 2004 (before SES was approved in Japan), BMS was electively, exclusively, and successfully placed in 519 de novo native coronary lesions, excluding patients over the age of 80 years and those with prior coronary artery bypass grafts (CABG). From August 2004 to May 2007 (the period that the paclitaxel-eluting stent (PES: TAXUS Express; Boston Scientific, Natick, MA, USA) was approved as a second drug-eluting stent (DES) in Japan), 68 lesions were treated using BMS and 1,444 lesions were treated using SES. Thus, the lesion-associated percentage of SES use among the entire cohort was 95.5%. The placement of SES or BMS after SES approval was not prospectively randomized. BMS was used for the following reasons: known malignancies and severe anemia required further investigation, inability to deliver SES to the target lesion, the preoperative state of the patient, lesions in the ectatic large artery, patients presented with an unknown clinical course (psychological instability or unconsciousness), and patients showed low compliance with drug continuation. Thus, we enrolled 2,031 consecutive lesions treated with either BMS (n=587) or SES (n=1,444). Informed consent was obtained from all patients prior to proceeding with stent placement. We retrospectively investigated the clinical and angiographic outcomes in October 2010. The follow-up coronary angiogram (fu CAG) was scheduled at approximately 6-12 months after BMS placement and at approximately 10-24 months for the SES group. The percentage patient follow-up for the fu CAG in the BMS group was 80.1% (470 lesions of 353 patients), and in the SES group was 82.8% (1, 195 lesions of 759 patients, p=0.16) ( Table 2) .
Percutaneous Coronary Intervention (PCI) procedures and anti-platelet therapy
PCI procedures are described in our previous reports (5) (6) (7) (8) (9) . The use of intravascular ultrasonography (IVUS) was encouraged to obtain intravascular assessment of vessel geometry and stent apposition. The IVUS guide was defined when intravascular assessment was carried out at least once during the procedure. High-pressure ballooning was generally performed. The diameter of the stent (stent diameter) was defined as the maximum diameter of balloon to dilate the stent at the target site. A rotablator was used in cases where the inflated balloon was indented (i.e., in cases where the balloon was not fully dilated, stents were implanted after pulverizing calcification by a rotablator) (7) . At bifurcate lesions, if there was a relatively large branch cross-overed by SES and a bifurcation 2-stent technique was performed, a final kissing balloon technique (KBT) was performed in almost all cases (5) . Culottes-stenting and T-stenting comprising stepped crushed, modified T, and conventional T-stenting techniques by SES were exclusively performed as a bifurcation 2-stent technique without prospective randomization.
Peri-procedural antiplatelet therapy was performed as previously reported (2, (5) (6) (7) (8) (9) . Ticlopidine (200 mg/day) was prescribed 10-14 days in advance of planned elective PCI. After a DES procedure, ticlopidine was prescribed for approximately 1 year, dependent upon the doctor's discretion. The precise incidence rate of ticlopidine allergy resulting in a change to clopidogrel (75 mg/day) or cilostazol (200-300 mg/day) is unknown, because ticlopidine allergy was not prospectively defined in terms such as degree of elevation of the serum level of enzymes due to liver damage.
Follow-up angiography and quantitative coronary artery angiography
The details of fu CAG and the quantitative coronary artery angiography (QCA) parameters were measured using the TCS cardiovascular network system, as described previously (6) (7) (8) (9) ; their values were obtained at 3 points: before PCI (preprocedural), immediately after successful PCI (postprocedural), and at the chronic phase (follow-up) (CAAS II system; Pie Medical, Maastricht, The Netherlands). Minimal lumen diameter (MLD), % diameter stenosis (%DS), reference diameter (RD), and lesion length were measured. In addition, acute gain (postprocedural MLD minus preprocedural MLD) and late luminal loss (postprocedural MLD minus MLD in the chronic phase) were calculated. Binary instent restenosis (binary restenosis) was defined as %DS < 50% in the chronic phase. Target lesion revascularization (TLR) after the fu CAG was defined as any (elective or emergency) repeated PCI or CABG performed, including ISR, at the 5-mm proximal and distal stent margins. The need for TLR was determined primarily based on visual angiographic outcome, although the patient's symptoms and the outcomes indicated by stress electrocardiograms, cardiac ultrasonography, and radionuclide images were also considered. In preprocedural occluded lesions, the preprocedural MLD was 0, and preprocedural % DS was estimated as 100.
Endpoints
The safety endpoints of the clinical outcomes (primary endpoint) were the composite of incidences of clinical cardiac events (target vessel failure), cardiac death, nonfatal recurrent MI (re-MI), the incidences of all (early, late, and very late) definite stent thrombosis (ST) (10) , and the severe angiographic in-stent restenosis (%DS !70 in the follow-up angiogram, usually considered as the clinical TLR). Angiographic binary restenosis (defined as above), as the efficacy endpoint of SES (secondary endpoint), was retrospectively compared with those of BMS.
Estimated variables
The definitions of the variables used as baseline patient, clinical, lesion, and procedural characteristics are provided here. The patient characteristics were as follows: age (age at primary stenting), male gender, diabetes (patients with diabetes mellitus), and low ejection cardiac dysfunction (ejection fraction of left ventricle less than 40 as evaluated by ultrasonography or left ventriculogram). Locations of the culprit lesion in the left anterior descending (LAD) artery and right coronary artery (RCA) were estimated. The following 5 clinical variables were defined according to the American College of Cardiology/American Heart Association classification of lesions: bifurcation (bifurcative lesions requiring any treatment of the side branch), chronic total occlusion (CTO) (total occlusion more than 3 months), diffuse lesion (diffuse, pre-procedural lesion length more than 15 mm), calcification (moderate and severe calcified lesions determined by angiogram), and ostial (ostial lesions). Particularly, the ostial lesion of RCA (RCA ostium) and the ostial lesion of left circumflex artery (LCx ostium) were estimated. Finally, procedural variables are as follows: stent number (number of implanted stents per lesion); stent diameter (maximum diameter of the balloon used to dilate the stent); stent length (length of the stented segment, calculated by adding the length of each stent, regardless of overlap); pressure (maximum pressure at the maximum inflation diameter of the balloon); side branch of bifurcation 2-stent technique (stented to the side branch of bifurcation performing any bifurcation 2-stent technique during the procedure); IVUS (availability of IVUS during PCI); and observational duration (duration in days until censored after the index procedure).
Statistics
Baseline characteristic variables are expressed as the mean value ± standard deviation (SD). Comparisons of variables between the BMS and SES groups were conducted using unpaired t-tests for continuous values and χ 2 tests for categorical values. A Cox proportional hazard model was used to analyze 28 variables as predictors of the primary endpoint and logistic regression analysis was used to analyze the predictors of secondary endpoints.
The strategy of treating coronary artery disease dramatically changed after the approval of SES. This was clearly reflected in the differences in 3 stent-related variables, namely, stent number, stent diameter, and stent length between SES and BMS (Table 1) . Therefore, it is important to compare these results between "the BMS era" and "the SES era." However, 3 stent-related variables of BMS after the approval of SES (n=68) were similar to those before the approval of SES (n=519) (p values were 0.77, 0.56, and 0.79, respectively). In addition, it was inappropriate to analyze endpoints in the SES-era cohort, because SES was used unrestrictedly. Therefore, the very small cohort of BMS after the approval of SES was added to the data of BMS before the approval of SES. Thus, the results of SES were examined largely through the historical comparison with those of BMS.
A difference was considered significant when the p-value was less than 0.05. STATA for Windows version 8 (StataCorp, College Station, TX, USA) was used for statistical analysis.
Results
Baseline characteristics
In Table 1 , 28 patient-related variables, lesion characteristics, procedural characteristics, and QCA parameters were compared between the BMS (n=587) and SES (n=1,444) groups. Among patient characteristics, the percentages of previous MI and low EF were significantly higher in the SES group than in the BMS group. Among lesion characteristics, the percentages of bifurcation, and diffuse, calcified, and LCx ostium differed significantly between the SES and BMS groups. Among procedural characteristics, the mean values of stent number, stent diameter, stent length, and pressure differed significantly between the SES and BMS groups. The percentages of direct stenting, side branch of bifurcation 2-stent, and IVUS differed significantly between the SES and BMS groups. Among the QCA parameters, the mean values of post-procedural MLD, post-procedural %DS, post-procedural RD, and acute gain differed significantly between the SES and BMS groups. Table 2 shows the primary endpoints in the BMS and SES groups. The lesion-based incidence of the primary endpoint was significantly lower in the SES group than in the BMS group. The observational interval was significantly shorter in the SES group than in the BMS group. The incidences of cardiac death and nonfatal re-MI did not differ between the SES and BMS groups. The percentage of severe restenosis was significantly lower in the SES group than in the BMS group.
Primary endpoints and definite stent thrombosis
The incidence of total definite STs in the SES group did not differ from that in the BMS group. The incidence of early definite ST was significantly lower in the SES group than in the BMS group. The incidences of late definite ST and very late ST in the SES group were not significantly different from those in the BMS group.
Predictors of primary endpoint
The predictors of the primary endpoint are shown in Table 3. SES, low EF, diffuse, hemodialysis, post-procedural %DS, and post-procedural RD were significant predictors of the primary endpoint. Bifurcation, CTO, direct stenting, and rotablator were not significantly related to the primary endpoint (HR ranged from 0.05 to 0.10). Baseline characteristics in the angiographic followup lesions Table 4 shows the baseline characteristics in angiographic follow-up lesions with SES (n=1,195) and BMS (n=470). In the SES group, 14 variables among patient, lesion, and procedural characteristics were significantly different from those in the BMS group, as shown in Table 1 . In addition, the percentage of patients with diabetes was significantly higher in the SES group than in the BMS group. 
Angiographic outcomes and secondary endpoint
The interval until angiographic follow-up was significantly longer in the SES group than in the BMS group. Among 12 QCA parameters at the 3 points, many variables differed between the 2 groups ( Table 5 ). The mean values of pre-procedural MLD, post-procedural MLD and %DS, acute gain, and followed-up MLD, %DS, RD, and lesion length in the SES group were significantly different from those in the BMS group (all p-values were <0.001, except pre-procedural MLD, p<0.05). The mean value of late luminal loss was significantly smaller in the SES group than in the BMS group. The incidences of binary restenosis and target lesion revascularization were significantly lower in the SES group than in the BMS group. Table 6 shows the results of logistic regression analysis used to determine the predictors of binary restenosis in the 1,665 angiographic followed-up lesions. Multivariate analysis indicated that SES, stent length, side branch of bifurcation 2-stent, stent diameter, and hemodialysis were the predictors of binary restenosis. CTO, acute gain, and diffuse were significant predictors of binary in-stent restenosis as determined by univariate analysis. Calcification and preprocedural %DS were not significant predictors using uni- variate analysis (p-values were near 0.05).
Predictors of binary restenosis
Discussion
We undertook this retrospective study with the aim of evaluating the mid-term (mean follow-up interval was approximately 4 years) safety and efficacy of SES used in a daily practice environment for de novo coronary stenosis in elective procedures after DES was approved in Japan. It is important to examine the outcomes of DES in a Japanese population because the incidence of ST (10), the major concern associated with DES, is known to be lower in Japan than in Western countries (1) (2) (3) (4) (5) . In addition, the lower incidence of ST in Japan is considered to be due to procedurerelated technical advantages (optimal stenting), such as the high-use ratio of IVUS and high-pressure ballooning (4-7). The better angiographic outcome of SES can be attributed to these procedure-related advantages.
The widespread indication of SES was reflected in many disadvantageous baselines, such as low EF; longer and larger number, but smaller diameter of stents for diffuse long lesions; bifurcation and bifurcation 2-stent techniques; and ostial lesions. These factors were consistently related to the incidence of cardiac events, binary in-stent restenosis, TLR, and ST (2, 4, (11) (12) (13) (14) (15) . However, SES was a protective factor of primary endpoint (Table 3 ). The incidence of cardiac death and non-fatal re-MI and that of definite ST were lower than those of a previous randomized trial from Western countries that followed 878 patients over 5 years (11.1% and 1.4%, respectively) (16) . Therefore, although the disadvantageous factors for the clinical events were partially excluded in that study (16) , the incidence of primary endpoints (6.6%) with a mean observational interval of more than 1,400 days (approximately 4 years) in the present study is acceptable (Table 2 ). In addition, the proportion of diabetic patients (more than 40%) in our study was higher than that in the previous study (less than 30%) (16) . Thus, although SES is widely used in daily practice in Japanese patients, we found that the mid-term clinical outcome of SES was favorable as determined through a historical comparison with BMS.
The angiographic efficacy of SES was primarily due to significant decreases in the mean value of late luminal loss (65.2% reduction) and the incidence of binary restenosis (46.6% reduction) and TLR (44.8% reduction) after the fu CAG compared to those of BMS (Table 4 ). This efficacy of SES is consistent with that reported in previous prospective studies (17, 18) . SES was a protective predictor of binary restenosis (Table 5) , although several adverse baseline characteristics were present in the SES group (Table 3 ). The mean value of late luminal loss (0.299 mm) and the incidence of binary restenosis (13.4%) were higher in the SES group (Table 4) than those in the cohorts studied in prospective randomized studies (ranging from -0.01 to 0.17 mm, and from 0% to 3.2%) (17, 18) . These differences reflect the fact that, in the present cohort, SES was used for complex lesions in a daily practice environment. Thus, the present study indicates the mid-term favorable safety and efficacy of SES for de novo native coronary lesions in a routine clinical setting. A further long-term observation is needed to clarify the durability of SES, because the long-term patency, such as VLST (4) and late catch-up phenomenon (19) , are unresolved concerns for SES.
Several limitations must be taken into account. First, the present study was a retrospective, non-randomized, and single-center analysis. The SES-use ratio after SES approval (95.5%) was very high. Thus, as described in the Methods, the outcomes of SES were compared with those of BMS through a historical comparison. The percentage of patients undergoing hemodialysis, a consistent powerful predictor of cardiac events and binary restenosis of SES (20) , was low in the present cohort compared to the Japanese large-scale registry (4). In addition, since the baselines were very different between BMS and SES groups (Table 1) , we did not apply the propensity matching score in this retrospective study. Second, the duration of dual antiplatelet therapy and choice of thienopyridine agent (ticlopidine or clopidogrel) to administer were dependent on the doctor's judgment. The number of patients who discontinued medical therapy, including the dual antiplatelet therapy, due to surgical and bleeding complications, was not fully examined nor was low compliance. However, there was no increase in the number of cardiac events or definite ST events (Table 2) . Third, other consistent predictors for cardiac events, such as medicines, renal dysfunction, and anemia, were not fully estimated. Fourth, since the former-generation BMS were largely enrolled, the durability of SES might be overestimated. Fifth, although the index procedures were mainly performed with IVUS (Table 1, 3) , intravascular assessment factors could not be evaluated. Sixth, the implication of stent fracture, the main cause of SES failure (21) , which should be estimated, including the findings of multislice computer tomography, was not fully estimated on the adverse outcomes (22) .
Conclusion
The mid-term (mean interval, 3.9 years) clinical and angiographic outcomes of SES in Japanese patients in a clinical practice setting were favorable, as largely determined by a historical and retrospective comparison with those of BMS.
The authors state that they have no Conflict of Interest (COI).
